文献速递肥胖与代谢综合征糖尿病

新视野:第二代肥胖药物治疗达标的新范式

New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

将肥胖视为慢性病,减重治疗的核心目标是防治并发症而非减重本身;许多并发症需减重10%–20%才能达标,但现有肥胖药物对多数患者无法实现≥10%减重。2021年6月司美格鲁肽2.4 mg/周获批用于慢性体重管理,3期试验显示其安慰剂校正减重>10%,逾半数患者减重≥15%,逾三分之一减重≥20%,效力约为现有肥胖药物的两倍,成为第二代肥胖药物的首个成员;第二代药物使基于生物标志物达标管理肥胖相关慢性病(ABCD)成为可能。

要点

  • 肥胖治疗核心是防治并发症,许多并发症需减重10%–20%才能达标。
  • 现有肥胖药物对多数患者无法实现≥10%减重。
  • 司美格鲁肽2.4 mg/周3期试验显示安慰剂校正减重>10%,逾半数减重≥15%,逾三分之一减重≥20%。

核心结论

  • 第二代肥胖药物使以体重为生物标志物达标管理肥胖相关慢性病(ABCD)成为可能,可像2型糖尿病、高血压和动脉粥样硬化一样按生物标志物目标治疗。

研究设计与样本

  • 本文为观点性文章,讨论以并发症为中心的美国临床内分泌学会(AACE)肥胖指南和肥胖相关慢性病(ABCD)诊断术语下的减重治疗策略。

主要发现

  • 许多并发症需减重10%–20%才能达到治疗目标;现有肥胖药物对多数患者无法实现≥10%减重。
  • 2021年6月司美格鲁肽2.4 mg/周获批用于慢性体重管理;3期临床试验显示其安慰剂校正减重>10%,逾半数患者减重≥15%,逾三分之一减重≥20%。
  • 司美格鲁肽效力约为现有肥胖药物的两倍,提供足以改善广泛并发症的减重幅度,成为第二代肥胖药物的首个成员。

关键数值与推荐

  • 许多并发症需减重10%–20%才能达到治疗目标。
  • 司美格鲁肽2.4 mg/周3期试验:安慰剂校正减重>10%,逾半数患者减重≥15%,逾三分之一减重≥20%。

临床怎么用

  • 以并发症为中心的AACE肥胖指南和ABCD诊断术语指导肥胖管理。
  • 第二代肥胖药物使体重可作为生物标志物,按与特定并发症防治相关的目标进行主动管理。
  • ABCD可像2型糖尿病、高血压和动脉粥样硬化一样,根据患者临床状态调整生物标志物目标(如HbA1c、血压、LDL-c)来防治相应并发症。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In treating obesity as a chronic disease, the essential goal of weight loss therapy is not the quantity of weight loss as an end unto itself but rather the prevention and treatment of complications to enhance health and mitigate morbidity and mortality. This perspective on obesity care is consistent with the complications-centric American Association of Clinical Endocrinology (AACE) obesity guidelines and the diagnostic term of adiposity-based chronic disease (ABCD). Many complications require 10% to 20% weight loss to achieve therapeutic goals; however, existing obesity medications fail to produce ≥10% weight loss in the majority of patients. In June, 2021, semaglutide 2.4 mg/week was approved for chronic weight management. Phase 3 clinical trials demonstrated that this medication produced > 10% placebo-subtracted weight loss, more than half of patents lost ≥15%, and over one third lost ≥20% of baseline weight. This essentially doubles effectiveness over existing obesity medications, provides sufficient weight loss to ameliorate a broad range of complications, and qualifies as the first member of a second-generation class of obesity medications. The advent of second-generation medications fully enables a treat-to-target approach for management of ABCD as a chronic disease. Specifically, with this degree of efficacy, second-generation medications permit active management of body weight as a biomarker to targets associated with effective treatment and prevention of specific complications. ABCD can now be managed similar to other chronic diseases such as type 2 diabetes, hypertension, and atherosclerosis, which are treated to biomarker targets that can be modified based on the clinical status of individual patients [ie, hemoglobin A1c (HbA1c), blood pressure, and low-density lipoprotein cholesterol (LDL-c)] to prevent the respective complications of these diseases.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Garvey WT. New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. J Clin Endocrinol Metab. 2022. PMID: 34865050. doi:10.1210/clinem/dgab848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。